Ablation of differentiated thyroid cancer (DTC) with recombinant human TSH (rhTSH): a comparison between 1850 MBq and 3700 MBq of radioiodine

被引：0
|
作者：
Capoccetti, F.
Pacini, F.
Vattimo, A.
Berbellini, A.
Cidda, C.
Fattori, S.
Ferretti, F.
Rossi, G.
Sivolella, S.
Pilli, T.
Guarino, E.
Burroni, L.
Castagna, M. G.
Cipri, C.
Brianzoni, E.
机构：
[1] Macerata Hosp, Nuc Med Oncol Dept, Macerata, Italy
[2] Univ Siena, Dept Endocrinol & Metab, I-53100 Siena, Italy
[3] Univ Siena, Dept Radiol, I-53100 Siena, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S160 / S160
页数：1
相关论文
共 50 条
  • [21] Radioiodine ablation of thyroid remnants in patients with differentiated thyroid carcinoma (DTC) following administration of rhTSH - a comparison with L-thyroxine withdrawal
    Baldys-Waligorska, Agata
    Golkowski, Filip
    Krzentowska-Korek, Anna
    Hubalewska-Dydejczyk, Alicja
    [J]. ENDOKRYNOLOGIA POLSKA, 2010, 61 (05) : 474 - 479
  • [22] Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH
    Sugino, Kimintori
    Ito, Koichi
    Takami, Hiroshi
    [J]. ENDOCRINE JOURNAL, 2006, 53 (06) : 723 - 728
  • [23] Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma
    Cherk, Martin H.
    Kalff, Victor
    Yap, Kenneth S. K.
    Bailey, Michael
    Topliss, Duncan
    Kelly, Michael J.
    [J]. CLINICAL ENDOCRINOLOGY, 2008, 69 (06) : 957 - 962
  • [24] Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer
    Durski, JM
    Weigel, RJ
    McDougall, IR
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2000, 21 (06) : 521 - 528
  • [25] Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan
    Hommel, I.
    Pieters, G. F.
    Rijnders, A. J. M.
    van Borren, M. M.
    de Boer, H.
    [J]. NETHERLANDS JOURNAL OF MEDICINE, 2016, 74 (04): : 152 - 157
  • [26] Thyroid radioiodine kinetics modification following recombinant human TSH (rhTSH) administration in multinodular goiter
    Bagnara, M. C.
    Calamia, I.
    Caorsi, V.
    Schiavo, M.
    Pomposelli, E.
    Reitano, C.
    Caputo, M.
    Giusti, M.
    Bagnasco, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S339 - S340
  • [27] What is the role of 1100 MBq (<30 mCi) radioiodine I-131 in the treatment of patients with differentiated thyroid cancer?
    VanWyngaarden, M
    McDougall, IR
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 1996, 17 (03) : 199 - 207
  • [28] The use of Recombinant Human Thyrotropin (rhTSH) in the Management of Differentiated Thyroid Cancer
    Skarulis M.C.
    [J]. Reviews in Endocrine and Metabolic Disorders, 2000, 1 (3) : 147 - 154
  • [29] Recombinant human TSH use in differentiated thyroid cancer
    Graf, Hans
    Paz-Filho, Gilberto
    [J]. ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2007, 51 (05) : 806 - 812
  • [30] Follow-up of differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after recombinant human thyrotropin (rhTSH) or thyroid hormone withdrawal
    Elisei, R.
    Corone, C.
    Driedger, A.
    Haugen, B. R.
    Kloos, R. T.
    Magner, J.
    Pacini, F.
    Luster, M.
    Schlumberger, M.
    Sherman, S.
    Pinchera, A.
    Ladenson, P. W.
    [J]. HORMONE RESEARCH, 2007, 68 : 33 - 33
12345